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The last 7 years have seen the treatment landscape for metastatic renal cell carcinoma
(mRCC) dramatically change as the understanding of the molecular background of the dis-
ease has grown. With the increase in treatment options, however, comes the question of
how best to maximise patient benefits based on the available medicines. This topic was
the key focus of a Pfizer meeting held at the 8th European International Kidney Cancer
Symposium (EIKCS) in Budapest, Hungary (3–4 May 2013), where leading oncology experts
reviewed the latest clinical trial evidence and discussed the importance of real world expe-
rience in treating patients with mRCC. This report offers an overview of the discussion on
how best to integrate clinical trial data, guideline recommendations and real world experi-
ence in order to make treatment decisions that will provide the maximum benefit for each
individual patient.1. Introduction
Only 7 years ago, there was a significant unmet need in the
treatment of metastatic renal cell carcinoma (mRCC) – immu-
notherapy was the only treatment available to patients, and
only a small subset of patients (5%) were responsive in
terms of long-term outcome.
The approval of sunitinib followed by six other targeted
agents to date have enabled significant improvements for pa-
tients in progression free survival (PFS) (Fig. 1), overall re-
sponse rate (ORR) and overall survival (OS) compared with
immunotherapy [1–7].
mRCC has become a dynamic therapeutic area,
where options for first-, second- and third-line treatmentseatment landscape: Buildin
KCS) on 3rd May, 2013 in
University of Vienna, D
uertel 18–20, A-1090 Vie
eduniwien.ac.at (M. Schmhave made long-term survival a realistic goal. As a conse-
quence, the clinical focus has shifted towards how to
best maximise long-term benefits for each individual patient
by optimising the treatment selection and management
based on both clinical trial results and real world experience.
On this basis, Pfizer organised and funded a meeting at the
8th European International Kidney Cancer Symposium
(EIKCS) that aimed to review how best to integrate clinical
trial data with real world experience when selecting and
managing treatments in first-, second- and third-line settings.
Achieving long-term survival requires a careful selection of
treatment for each individual patient combined with an effec-
tive management of adverse events (AEs) and dosing to max-
imise treatment duration. How can physicians best use theg on evidence and experience’ meeting held at the 8th European
Budapest, Hungary
epartment of Medicine I, Clinical Division of Oncology and
nna, Austria.
idinger).
Fig. 1 – The availability of targeted agents for the treatment of mRCC has significantly improved patients’ median progression
free survival. Slide courtesy of Professor Manuela Schmidinger, 2013.
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choose the most appropriate treatment sequence for their
patients?
Reviewing the recent developments in mRCC treatment,
Doctor James Larkin, from the Royal Marsden Hospital (Lon-
don), discussed the most recent treatment guidelines issued
by the European Society for Medical Oncology (ESMO) and
highlighted the critical updates to the recommendations in
second- and third-line treatments.
Focusing on the most recent clinical data on first-line treat-
ments, Doctor Camillo Porta from IRCCS San Matteo University
Hospital Foundation (Pavia) provided an in-depth look at the
challenges and opportunities that non-inferiority trials offer
and how to put their results in context whenmaking decisions
in the clinic.
Finally, Professor Manuela Schmidinger from the Medical
University of Vienna brought the discussion back to the pa-
tient, illustrating how real world experience has influenced
treatment decisions through a number of patient case
studies.
2. The mRCC treatment landscape: Where are
we now?
Doctor James Larkin, Royal Marsden Hos-
pital, London, UK
James Larkin is a Consultant Medical Oncol-
ogist at The Royal Marsden, London, United
Kingdom(UK), specialising in the treatmentof
patients with cancer of the kidney and can-
cers of the skin, including melanoma. Dr.
Larkin received a first in Natural Sciences
from the University of Cambridge and
undertookclinical trainingat theUniversityof
Oxford, qualifying in 1996. He underwent
general medical training in London, and in 2001 won a Medical
Research Council Fellowship for a Clinician, carrying out laboratory
research at The Institute of Cancer Research (ICR), which led to the
award of a PhD. He completed specialist training at The Royal
Marsden and was appointed a Consultant in 2008.His research interests include the individualisation of patient
treatment inkidneycancerandmelanoma, and the combinationof
novel targeted therapies to treat these diseases. He is UK Chief
Investigator for a number of clinical trials inmelanoma and kidney
cancer and has been awarded research grants from bodies
including Cancer Research UK, Wellcome Trust and the European
Framework Programme. He is a member of the National Cancer
Research Institute (NCRI) Melanoma Clinical Studies Group and
Chair of both theNCRIRenal CancerClinical StudiesGroupandThe
Royal Marsden/ICR Committee for Clinical Research.
James Larkin opened his presentation by highlighting the
necessary components for achieving longer-term survival in
mRCC (Fig. 2).
While efficacy has been demonstrated for first-line treat-
ment options, andphysiciansunderstand thatmanaging these
agents effectively and proactively is critical to achieving the
best outcome, longer-term survival is now also dependent on
developing the best sequencing strategy with treatments fol-
lowing first-line therapies. This option is only now truly being
implemented in day-to-day practice as, for the first time, phy-
sicians and patients have proven efficacious treatments avail-
able to them in both second- and third-line settings.
The recent RCC treatment guidelines, published by ESMO
in October 2012, use the most comprehensive review of clini-
cal evidence to provide recommendations for treatment –
guidance that enables physicians to extend the lives of their
patients with mRCC. The current update represents a step for-
ward in the management of mRCC with the inclusion, for the
first time, of a next-generation VEGF receptor tyrosine kinase
inhibitor (TKI) – recommending axitinib in second-line and a
third-line option with everolimus [8].
The evidence for axitinib in second-line is based on the
AXIS trial, the first phase III, head-to-head study against a
targeted agent in second-line mRCC. Patients with clear cell
mRCC who had failed on one first-line treatment with suniti-
nib, bevacizumab + interferon alpha (IFN-a), temsirolimus or
cytokines (n = 723) were randomised to receive either 5 mg
axitinib twice a day (BID) or 400 mg sorafenib BID. The pri-
Fig. 2 – There are four necessary components to achieving longer-term survival for patients with mRCC. Slide courtesy of
Doctor James Larkin, 2013.
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(ITT) population, with patients on axitinib achieving a median
duration of progression free survival (mPFS) of 6.8 months
significantly superior to 4.7 months for patients receiving
sorafenib (HR 0.67; p < 0.0001) [9].
Looking more closely at the largest patient subgroup, pa-
tients who had first-line treatment with sunitinib (n = 389)
achieved a mPFS of 4.8 months when given axitinib in sec-
ond-line, comparedwith 3.4 months for sorafenib (Hazard Ra-
tio [HR] 0.741; p = 0.011), a 41% longer mPFS with axitinib in
second-line, post-sunitinib versus sorafenib. In the second
largest subgroup, patients who had first-line treatment with
cytokines (n = 251) achieved an mPFS of 12.1 months with axi-
tinib versus 6.5 months with sorafenib (HR 0.464; p < 0.0001)
[9].Case Study: Sunitinib from Prof Schmidinger:
Managing AEs to Maximise Patient Response
Patient: Male, 64 years
History:
• October 2011 – Nephrectomy due to clear cell RCC, pT3b,
• November 2011 – Diagnosed with metastatic disease with
• MSKCC prognosis: Intermediate
• ECOG: 0
Treatment:
• Sunitinib, 50 mg 4/2 initiated November 2011
Details:
• After beginning initial treatment, patient experienced hyp
and achieved partial remission
• 11 months after starting treatment, experienced minor di
• At this time, patient was no longer experiencing hyperten
• Dose was escalated to 62.5 mg 4/2, and patient experience
• Patient is still continuing treatment with an ongoing PFSDr. Larkin highlighted that, in addition to these important
efficacy results, the other critical information given in the
trial was on AEs. Firstly, AEs, such as hypertension and fati-
gue, would be expected with a potent TKI, as they are on-tar-
get side effects that indicate the treatment is effective.
Secondly, the list of AEs allows physicians to identify which
of the side effects can be effectively managed, such as hyper-
tension and nausea, and those that may be more difficult,
such as alopecia. Dr. Larkin warned, however, that physicians
do need to keep in mind that some AEs, such as alopecia, may
not be medically serious, but are not trivial for a patient, and
discussions with patients should be comprehensive and clear
from the beginning of treatment.
We now have a wealth of clinical trial data to inform our
treatment decisions in second-line, but clinical experiencepNx, pM+, G2
sites in lung, lymph nodes, bone and liver
ertension grade 2, was prescribed antihypertensive agents,
sease progression
sion and had discontinued antihypertensive agents
d again hypertension grade 2 (no additional side effects)
of 17 months
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ventional, population-based studies indeed also provide in-
sights into outcomes with agents in real-life clinical
settings and in patients who may not necessarily be included
in clinical trials.
Advancing from second-line treatment, physicians should
now consider treatment in the third-line setting to achieve a
long-term continuum of care. The only treatment recom-
mended at this stage in this setting, post two TKIs, is everol-
imus, based on the best available evidence to date: the
RECORD-1 trial results. In this phase III trial, mRCC patients
who received prior treatment with a TKI were randomised
to receive either everolimus or placebo (n = 416). Importantly,
only 21% of patients in the trial received everolimus in sec-
ond-line, the remaining 79% received the treatment in a sub-
sequent setting (Fig. 3) [10,11].
Based on the 108 patients (26%) who had received two pre-
vious TKIs, the results demonstrate clear activity for everoli-
mus in third-line, achieving a mPFS of 4 months in patients
previously treated with sunitinib and sorafenib, compared
to a mPFS of 1.84 months in patients receiving placebo (HR
0.32; p < 0.001) [12,13].
Returning to the question of how physicians can apply the
results of these trials to their patients, Dr. Larkin stated it is
important to draw on real world experience, as patients in
the clinic may be different from those in a clinical trial. While
efficacy remains the key driver for treatment selection,
choices may also be informed and affected by safety profiles
and side effects, especially with patients who may have addi-
tional health considerations.
In conclusion, efficacy and evidence support the use of
axitinib in second-line after first-line treatment with suniti-
nib, with everolimus as the proven option for treatment in
third-line. Based on the highest level of evidence, reflected
by the recently updated ESMO 2012 RCC treatment guidelines,
the recommended treatment sequence to maximise patient
outcomes is TKI–TKI–mTOR inhibitor.Fig. 3 – Patients who had received prior treatment with a TKI were
either everolimus or placebo. 21% of patients in the trial received e
treatment in a subsequent setting. Slide courtesy of Doctor James‘We all have to use our clinical experience to maximise the ben-
efits of this sequence for our patients, helping control the mRCC
in our patients for as long as we can,’ stated Dr. Larkin.3. First-line treatment of mRCC: Providing
clinical context
Doctor Camillo Porta, IRCCS San Matteo
University Hospital Foundation, Pavia, Italy
Camillo Porta is a Senior Staff Member of
the Unit of Medical Oncology at the IRCCS
San Matteo University Hospital Foundation
in Pavia, Italy. He is also an Adjunct Pro-
fessor of Medical Oncology at the Post-
graduate Schools of Medical Oncology,
Biotechnology and General Surgery at the
University of Pavia.
After specialising in medical oncology
with honours at the University of Pavia, Dr. Porta undertook an
Oncology Research Fellowship at the IRCCS San Matteo University
Hospital. His research interests include free radicals in cancer;
immunology of tumours; development of novel anticancer
agents; and the biology of malignant mesothelioma, hepatocel-
lular carcinoma and renal cell carcinoma. Dr. Porta was awarded a
prize from Schering-Plough in 1997 for his experimental work on
free radicals, free radical scavengers and cancer, and the Gaetano
Fichera Memorial Prize in Medical Oncology from the University
of Pavia in 1999. Dr. Porta is the author of more than 150 original
papers published in peer-reviewed journals, including the New
England Journal of Medicine, The Lancet, Lancet Oncology, European
Urology, Proceedings of the National Academy of Sciences, and the
Journal of Clinical Oncology. He is Editor-in-Chief of Oncology Reviews
and is a reviewer of several international journals.
Treatment guidelines are extremely important tools that
provide physicians with a critical review of the available
evidence to support first-line treatment decisions. Numerous
guidelines are available; however the five levels of evidence
and grades of recommendation adopted by the ESMO 2012randomised in the RECORD-1 phase III trial to receive
verolimus in second-line, the remaining 79% received the
Larkin, 2013.
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resource.
First-line treatment of mRCC has been revolutionised with
the approval in European countries of three treatments for
good and intermediate prognosis patients, sunitinib, pazopa-
nib and bevacizumab + IFN-a, and temsirolimus for poor
prognosis patients. Efficacy is the key driver when selecting
first-line treatment, but treatment choice is also informed
by robust evidence and guideline recommendations, patient
characteristics, experience and patient preference.
The ESMO 2012 RCC treatment guidelines differentiate
sunitinib from the other treatment options, as it alone has
the highest level of evidence and grade of recommendation
for good and intermediate prognosis patients, together with
temsirolimus as the recommendation for poor prognosis pa-
tients. The rationale behind this recommendation is evident
when the results from the pivotal trials are examined. Suniti-
nib has shown an unsurpassed efficacy across multiple clini-
cal endpoints: mPFS (11 months), median overall survival
(mOS, 26.4 months), and ORR (47%) versus IFN-a (Fig. 4)
[1,3,5–7,14–16].
Following the publication of the ESMO 2012 RCC treatment
guidelines, however, results from the COMPARZ trial were an-
nounced at the 2012 ESMO Congress, providing additional
information that could impact treatment choice in first-line.
The question, Dr. Porta asked, is whether they should.
The aim of the open label, phase III COMPARZ non-inferi-
ority trial was to provide a direct comparison of the efficacy,
safety and tolerability of pazopanib and sunitinib in first-line
mRCC. As the first non-inferiority (NI) trial in mRCC, the pri-
mary objective was to determine whether patient response to
pazopanib was not clinically inferior to sunitinib, which was
defined as being met if the upper bound of 95% confidence
interval (CI) for HR < 1.25, though the European Medicines
Agency (EMA) had requested 6 1.22 [4].
Initial trial enrolment included 927 patients; however the
trial was later combined with a similar phase II trial being
conducted in Asia to bring the total number to 1,110. PatientsFig. 4 – Sunitinib has shown an unsurpassed efficacy across mP
IFN-a. Slide courtesy of Doctor Camillo Porta, 2013.were randomised to receive either pazopanib 800 mg daily on
a continuous dosing schedule or sunitinib 50 mg daily on a
4 weeks on/2 weeks off (4/2) schedule. With a mPFS of
8.4 months for patients receiving pazopanib compared with
9.5 months with sunitinib, despite a 1.1 month difference,
the results, initially presented at the 2012 ESMO Congress,
based on the ITT analysis, seem to indicate non-inferiority
of pazopanib versus the standard of care, sunitinib [4].
A number of other NI trials are being conducted in mRCC,
and as NI trials become more common, it will be critical for
physicians to understand the specificities of analysing the
results of these trials (as opposed to superiority trials) in
order to determine if and how they should impact clinical
practice.
Dr. Porta highlighted that one key to interpreting these NI
trials lies in the two patient populations for analysis: the ITT
population, which includes all randomised patients (e.g. non-
compliant patients, protocol violations, etc.) and the Per Pro-
tocol (PP) population, which are only the patients who com-
pleted the study without protocol violations. ITT and PP
analyses are equally important when drawing conclusions
from a NI trial as the PP analysis is the most conservative
assessment. Both analyses should, hence, lead to similar con-
clusions for a robust interpretation of NI trials. Therefore,
reporting results from just one of these populations may have
an impact on the interpretation of the data.
Returning to the COMPARZ trial, Dr. Porta reviewed the re-
sults for these two populations, demonstrating that non-infe-
riority was only reached in the ITT group, but not in the PP
population where the upper bound of the 95% CI crossed
the NI margin, as defined by the study protocol (1.25) and
the EMA (1.22) [17]. Taking the results from both the ITT and
PP analyses into account, as is recommended for NI trials,
the level of uncertainty about the reproducibility of this NI
trial in the real world remains high.
In addition, the methodology used to collect the quality of
life (QoL) data included surveying patients at day 28 of the
sunitinib treatment [18], which has been demonstrated toFS (11 months), mOS (26.4 months) and ORR (47%) versus
Case Study: Sunitinib from Prof Schmidinger:
Optimising First-line Treatment Response by Maximising Treatment Dose/Duration
Patient: Male, 44 years
History:
• November 2010 – Cytoreductive nephrectomy, clear cell RCC, pT3a, pN0, G3
• Metastases included lesion in the left kidney, left adrenal gland, cauda pancreatic, left thoracic wall, left paraaortic lymph
nodes, lung, bone and pleural effusion
• MSKCC prognosis: Intermediate
Treatment:
• Sunitinib, 50 mg 4/2 initiated December 2010
Details:
• Patient clearly informed about dose-response
• Experienced hypertension grade 3, stomatitis grade 1 and anorexia with significant weight loss during 4 weeks on treat-
ment
• Dose reduction suggested to manage anorexia, patient declined due to concern over long-term outcome
• Anorexia managed by addition of medroxyprogesteronacetate
• Patient experienced partial remission with current PFS (still ongoing) of 24 months
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cycle. Despite this, while statistical significance was observed
for the two pre-specified primary QoL measurements, the dif-
ferences in QoL assessments between pazopanib and suniti-
nib were lower than the validated, minimally important
difference, and may not carry a clinically meaningful differ-
ence for patients.
Moving to optimal treatment options for patients with
poor prognosis, Dr. Porta stated that, while the vast majority
of trials have not considered patients with poor risk, temsirol-
imus is the only treatment that has been examined in this
population. Survival data from the global trial for advanced
renal cell carcinoma (ARCC) showed a 49% increase in median
OS with temsirolimus compared with IFN-a, the first and only
study to demonstrate a significant improvement in OS for pa-
tients with poor prognosis [16].
Overall, when translating results from clinical trials, expe-
rience is still an important consideration, as clearly demon-
strated for sunitinib. Since its approval 7 years ago,
physicians have had the opportunity to learn how to manage
patients on sunitinib and its related AEs optimally. Experience
in the real world has demonstrated that some toxicities with
sunitinib, such as hypertension, can be considered biomark-
ers of treatment efficacy. Recent data show a link between in-
creased PFS and OS in patients who developed hypertension
on treatment compared with patients who did not [19,20]. In
addition, clinical experience and published evidence indicate
that efficacy is of utmost importance to cancer patients, and
patients with mRCC are most often accepting of some AEs
based on the understanding that they may be linked to im-
proved efficacy [21].
Efficacy is, and should continue to be, the primary treat-
ment decision driver. In determining the most efficacious
treatment, physicians have many tools available to them,
including the ESMO2012 RCC treatment guidelines,whichpro-
vide a critical reviewof all available evidence to help clinicians.Basedon this assessment, the best recommendationwas given
to sunitinib for patientswith good and intermediate prognosis
and temsirolimus for patients with poor prognosis.‘At the end of the day, it is the physician’s choice to choose the
best treatment for the patient and it is clear that [sunitinib and
temsirolimus] should be regarded as the first-line treatments of
choice in their respective risk groups,’ concluded Dr. Porta.4. Learning from real-life clinical cases
Professor Manuela Schmidinger, Depart-
ment of Oncology, Medical University of
Vienna, Vienna, Austria
Manuela Schmidinger is a Medical Oncolo-
gist and Professor of Medicine at the Uni-
versity of Vienna, Vienna, Austria. Having
achieved official specialisation in intensive
care medicine, she is currently a Senior
Physician in the Department of Oncology
and Programme Director for mRCC, leading
the research programme in the field of
kidney cancer and the care of patients with RCC.
Her research interests include prognostic factors and treat-
ment in RCC, TKI-related side effects and quality of life mea-
surements in long-term survivors of cancer. Professor
Schmidinger is the author or co-author of more than 50 articles in
peer-reviewed journals, including Anticancer Research, Journal of
Immunotherapy, Supportive Care in Cancer, Oncologist, Breast Cancer
Research and Treatment, British Journal of Cancer, Journal of Clinical
Oncology, Cancer and Leukaemia & Lymphoma. She is also the author
or co-author of four books in the field of immunology and
oncology, including a recent textbook on targeted agents in
kidney cancer.
Physicians need to manage the risk that the outcome for
patients in daily practice may not meet the expectations from
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 –8 7the trial, as many patients may have co-morbidities and other
challenges that can impact response to treatment. Drawing
on personal experience with patients, Prof Schmidinger re-
lated the important principles that should guide physicians
when treating patients.
Avoiding unnecessary treatment discontinuation and
maintaining drug dose are two critical factors to maximising
treatment benefits for patients. Conducting clear and com-
prehensive discussions with patients on the subjects of
dose/response and the link between certain AEs (e.g. hyper-
tension) and outcome involves the patient in their treatment
and provides them with essential information that can im-
pact their treatment decisions.
The case of a 44-year-old woman illustrates this point. In
September 2012, the patient presentedwith a history of cough
since June 2012, fever and ECOG PS 0. A computed tomogra-
phy (CT) scan revealed multiple lung lesions, a tumour in
the right kidney, most likely RCC, and additional metastases
in the liver, bone and pericardium. After a palliative nephrec-
tomy (G3, pT3a, L0 and V1), she was MSKCC (Memorial Sloan-
Kettering Cancer Center) and Heng-classified intermediate
risk and was put on sunitinib, 50 mg once daily on 4/2 treat-
ment cycle that same month. The patient was informed at
the beginning on the incidence, severity and prophylactic
measures of the side effects, as well as the possible relation-
ship between dose/response and as a biomarker of successful
outcome.
Four days after beginning treatment she was admitted to
hospital with chest pain and high blood pressure. Her ECG
(electrocardiogram) and cTNT (cardiac troponin T) was nor-
mal and a CT showed no evidence of embolism, but her
blood pressure was 190/110 mmHg. After she was prescribed
analgesics and antihypertensive agents, the treating physi-
cian recommended she discontinue sunitinib treatment or
request dose reduction. The patient refused based on her
understanding of the association with hypertension and
efficacy and instead was prescribed additional hypertensive
agents. In the end, the patient was right and she experi-
enced a dramatic response within the first weeks of treat-
ment, demonstrating the importance of informing patients
about the role of side effects and their potential impact
on outcome, as it can be critical in avoiding unnecessary
treatment discontinuation.
In addition, when managing patients, physicians need to
be critical of what constitutes disease progression due to
drug resistance. For example, a male patient, 71 years old,
was diagnosed with clear cell mRCC and underwent a
nephrectomy in 1989. In December 2008, he underwent a
partial resection of liver segment IV due to liver metastases,
with new lesions diagnosed in August 2009. His prognosis
was favourable based on MSKCC data and he was referred
to the department of oncology where he began treatment
on sunitinib, 50 mg once daily on 4/2 treatment cycle. He
experienced grade 3 hypertension, grade 2 fatigue, and
grade 1 diarrhoea and hand-foot syndrome. In November
2009, he achieved partial remission and his dose was re-
duced to 37.5 mg due to mucositis. He maintained partial
remission and achieved complete remission in August
2010 on this dose.Concerned about the chronic use of medicine, the patient
then requested a further dose reduction to 25 mg. Fifteen
months after initiating sunitinib treatment, scans indicated
that he had disease progression. Instead of assuming treat-
ment resistance, his dose was re-escalated to 50 mg. He has
since achieved a PFS of 33 months, and an OS of 42+ months
since starting systemic treatment. His progression was due to
inappropriate dosing, not treatment resistance, highlighting
the need for physicians to question when disease progression
indicates apparent resistance due to dose levels or true disease
resistance.
Prof Schmidinger concluded that the past 7 years of expe-
rience with targeted agents has increased physicians’ knowl-
edge substantially on how to best use these new agents, as
evidenced by the rapidly growing number of long-term survi-
vors. Therefore, as the field continues to advance, efficacy
should continue to remain the primary goal, so that physi-
cians not only select the first-line treatment with care, but
must also ensure they are managing it as effectively as
possible.‘If we [. . .] try to get the best out of every treatment line, I think
we will achieve survival that surpasses what we have seen in
clinical trials,’ concluded Prof Schmidinger.5. Conclusions
• Efficacy is the key driver of treatment selection.
• Guidelines provide a critical review of available evidence,
helping clinicians to select the most appropriate treat-
ment; ESMO 2012 RCC treatment guidelines acknowledge
the highest level of evidence for sunitinib and temsiroli-
mus in first-line for their respective patient populations.
• Evidence supports sequencing as TKI–TKI–mTOR inhibitor,
with axitinib demonstrating proven efficacy in second-line
after first-line sunitinib or a cytokine, and everolimus as
the only agent recommended in a third-line setting.
• It is important that every targeted agent, whether in first-,
second- and third-line, is used effectively in order to max-
imise their treatment benefits and obtain optimal clinical
outcomes.
• Achieving the best patient outcomes depends on individu-
alising dosing, maximising treatment duration and effec-
tively managing AEs.Conflict of interest statement
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